September 21st 2023
In the first article of this series, Nilay Gandhi, MD, explains the treatment and management of patients with advanced/metastatic prostate cancer and details the options for androgen deprivation therapy.
September 17th 2023
September 13th 2023
Expert Illustrations & Commentaries™: The Role of Radioligand Therapy in mCRPC and How It Could Impact Your Practice in the Future
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Register Now!
New Targets, New Treatments, and New Combinations for the Management of Advanced Prostate Cancer
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Medical Crossfire®: Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: What the Community Needs to Know to Apply RLT in PSMA-Positive mCRPC in Context with Current Treatment Paradigms
View More
Oral chemotherapy shows initial promise in treatment-resistant prostate cancer
July 14th 2023"The beauty is, now we can deliver a cisplatin-based chemotherapeutic orally, which is usually never done. And by targeting the prostate, we can reduce kidney and liver toxicity and the risk of peripheral neuropathy," says Shanta Dhar, PhD.
Inflation Reduction Act may lower patients' Medicare costs for prostate cancer treatment
July 13th 2023"Within the Inflation Reduction Act, there is a provision that will cap the out-of-pocket contribution for Medicare beneficiaries, dropping to $3250 in 2024, as well as $2,000 in 2025," says Brian Cortese.
PSMA-Based Imaging and Theranostics: A Summary of Current Paradigm Shifts and a Look to the Future
July 11th 2023The panel discusses the possibility of PSMA-PET becoming the standard-of-care imaging modality for prostate cancer, which may obviate the need for conventional imaging and bone scans, and then touches on the increasing availability of PSMA-targeted radiotherapies.
Analysis further links prostate cancer drug class with cognitive and functional toxicity
July 5th 2023“To our knowledge, these results are the first to suggest an association between second-generation [antiandrogens] and cognitive and functional toxic effects based on data from prospective [randomized controlled trials],” the investigators wrote.
Dr. Conor Driscoll on the effect of TNF alpha inhibitor use on prostate cancer risk
July 4th 2023"I would say that the take-home message of the study is that these immunosuppressive medications have alterations in the microbiology in a lot of these organs and a lot of these tumors," says Conor Driscoll, MD.
Long-term TNF alpha inhibitor use linked with decreased risk of prostate cancer
June 30th 2023"Prostate cancer showed a decreased risk, which we thought was very interesting, because it was the only cancer for which that signal existed, that there is possibly a protective effect of these medications," says Conor Driscoll, MD.
Evolving Practice Standards: Perirectal Spacing for Prostate Cancer
June 30th 2023In the first installment of this series, Juan Montoya, MD, discusses the results of the phase 3 pivotal trial of a polyethylene glycol-based hydrogel spacer, reviews real-world data on this product, and provides insights on the evolving practice standards for perirectal spacing in prostate cancer.
Diagnostics company opens new facility to scale up production of IsoPSA test for prostate cancer
June 29th 2023The new space includes a clinical laboratory for IsoPSA testing, labs for research and development, offices, and manufacturing spaces for production and distribution of in vitro diagnostic kits.
Dr. Basralian discusses the benefits of focal therapy in prostate cancer
June 29th 2023"Catheters go in, [and] they come out within 2 to 3 days for my patients. Therefore, the perioperative period is very easy for patients, whereas radical surgery requires catheters for 7 to 10 days," says Kevin R. Basralian, MD.
Expert: Partners should be included in sexual recovery process in prostate cancer
June 25th 2023“The take-home message of this research is that, given the importance of partners in the prostate cancer sexual recovery process and the impact of prostate cancer on partners' sex lives, we should seek to include partners in the sexual recovery process as part of routine survivorship care,” says Natasha Gupta, MD.
Financial toxicity is a growing concern in urologic oncology
June 23rd 2023"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.
Study examines molecular alterations in intraductal carcinoma of the prostate
June 23rd 2023“We found some BRCA1 and BRCA2 mutations, as well as CDK12 mutations, in our cohort of patients with intraductal carcinoma of the prostate. Those are things that you could use now for clinical decision-making with PARP inhibitors with their approved indications,” says Benjamin Miron, MD.